10/F, Tower B, China Pacific Insurance Plaza
28 Fengsheng Hutong, Xicheng District
Beijing 100032, China
Tel: + (86 10) 5776 3888
Fax: + (86 10) 5776 3777
Current position: Managing Partner of Tian Yuan Law Firm and Head of Tian Yuan Law Firm Hong Kong Office.
Practice area/industry focus: Capital markets, especially the overseas IPO area
Career highlights: Since 2017, Mr. Fu has completed 24 IPOs both in U.S. and HK covering TMT, healthcare, fintech, real estate and other traditional industries, among which, the most significant ones are as below:
- Qudian Inc. (QD.NYSE) - the largest IPO among all the U.S. listed China concept stocks in fintech industry;
- Bilibili Inc. (BILI.Nasdaq) - one of the most popular Chinese internet entertainment communities for young people;
- Ascletis Pharma Inc. (1672.HK) - the first company listed in HK using the latest amended listing rules for biotech companies. Rewarded as “Deal of the Year” in 2018 by China Business Law Journal;
- Midea Real Estate Holding Limited (3990.HK) - the largest HK IPO in real estate industry in 2018;
- Shanghai Junshi Biosciences Co., Ltd. (1877.HK) - the first NEEQ-listed Chinese company listed in HK;
- Jinxin Fertility Group Limited (1951.HK) - the only medical company listed in HK with market value exceeding HK$20 billion;
- Hansoh Pharmaceutical Group Company Limited (3692.HK) - the largest pharmaceutical HK IPO in 2019 with fundraising exceeding US$1 billion.
Asialaw Distinguished Practitioner 2020 in Capital Markets